awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q28083386-96FB9CD6-032D-43A6-9A0A-A65183CE0DDE
Q28083386-96FB9CD6-032D-43A6-9A0A-A65183CE0DDE
BestRank
Statement
http://www.wikidata.org/entity/statement/Q28083386-96FB9CD6-032D-43A6-9A0A-A65183CE0DDE
ALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome it
P2860
Q28083386-96FB9CD6-032D-43A6-9A0A-A65183CE0DDE
BestRank
Statement
http://www.wikidata.org/entity/statement/Q28083386-96FB9CD6-032D-43A6-9A0A-A65183CE0DDE
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
09eb958db3e64651c3d8fd29777cb9f79cc99ea9
P2860
CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study.